Venrock Healthcare Capital Partners III, L.P., 10% Owner at KalVista Pharmaceuticals, Inc. (KALV), bought 227,700 shares at $12.44 ($2.8M) on 2024-01-08, disclosed to the SEC on 2024-01-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.44 | 69,184 | $861K | 30.2% |
| 2 | $12.44 | 69,184 | $861K | 30.2% |
| 3 | $12.56 | 20,816 | $261K | 9.2% |
| 4 | $12.56 | 20,816 | $261K | 9.2% |
| 5 | $12.67 | 47,700 | $604K | 21.2% |
| Total | $12.51 avg | 227,700 |
| $2.8M |
| 100% |
| Filing → |
| KALV | BUY | 2024-02-01 | $2.5M | — | Filing → |
| KALV | BUY | 2024-01-29 | $1.4M | — | Filing → |
| UMRX | BUY | 2020-08-18 | $1.4M | — | Filing → |